October 5, 2020 -- The U.S. Food and Drug Administration (FDA) has awarded LabCorp emergency use authorization (EUA) for a new, high-throughput method that uses heat and technology to extract RNA from COVID-19 samples.
The method will improve the speed and efficiency of reverse transcription polymerase chain reaction (RT-PCR) tests, which are considered the gold standard. The heat extraction process traps viral particles and eliminates the need for RNA extraction reagents to capture and concentrate viral nucleic acid, which improves testing efficiency and cuts down on testing supplies.
The firm also announced it received an FDA EUA for the use of matrixed pooling on samples collected outside a healthcare setting via its Pixel by LabCorp and LabCorp At Home COVID-19 test kits. The matrixed pooling authorization for at-home collection is an extension of the FDA EUA issued on July 24.
When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.Yes, Keep Me Current